A Series E funding round led by Goldman Sachs has brought in $40 million for T2 Biosystems. The Lexington, Mass.-based company will use the money to develop and commercialize its T2Candida test, which can detect Candida fungal infections known to cause sepsis from whole blood samples in under two hours.
T2 Biosystems pulls in $40M in Series E funding round
SmartBrief Job Listings for Health Care
|Compliance and Ethics Director||
Sysmex America, Inc.
|Director, Site Quality Management||
|Palm Springs, CA|
|Compliance Officer-Medical Products||
W. L. Gore